Cargando…

Understanding and preventing type 1 diabetes through the unique working model of TrialNet

Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Battaglia, Manuela, Anderson, Mark S., Buckner, Jane H., Geyer, Susan M., Gottlieb, Peter A., Kay, Thomas W. H., Lernmark, Åke, Muller, Sarah, Pugliese, Alberto, Roep, Bart O., Greenbaum, Carla J., Peakman, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838353/ https://www.ncbi.nlm.nih.gov/pubmed/28770323 http://dx.doi.org/10.1007/s00125-017-4384-2

Ejemplares similares

Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care 2019;42:2228–2236
por: Sims, Emily K., et al.
Publicado: (2020)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073
por: Greenbaum, Carla J., et al.
Publicado: (2013)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Naturally Arising Human CD4 T-Cells That Recognize Islet Autoantigens and Secrete Interleukin-10 Regulate Proinflammatory T-Cell Responses via Linked Suppression
por: Tree, Timothy I.M., et al.
Publicado: (2010)

Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073
por: Rios, Paola, et al.
Publicado: (2013)

Innate and adaptive immunity to human beta cell lines: implications for beta cell therapy
por: van der Torren, Cornelis R., et al.
Publicado: (2015)

Understanding .NET
por: Chappell, David
Publicado: (2006)

Depleting T Cells in Newly Diagnosed Autoimmune (Type 1) Diabetes—Are We Getting Anywhere?
por: Lernmark, Åke
Publicado: (2013)

Etiology of Autoimmune Islet Disease: Timing Is Everything
por: Lernmark, Åke
Publicado: (2021)

Simultaneous Detection of Circulating Autoreactive CD8(+) T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers
por: Velthuis, Jurjen H., et al.
Publicado: (2010)

Immunogenicity of human embryonic stem cell-derived beta cells
por: van der Torren, Cornelis R., et al.
Publicado: (2016)

β-Cells, Autoimmunity, and the Innate Immune System: “un Ménage á Trois”?
por: Roep, Bart O.
Publicado: (2013)

There Is Something About Insulin Granules
por: Roep, Bart O.
Publicado: (2020)

The need and benefit of immune monitoring to define patient and disease heterogeneity, mechanisms of therapeutic action and efficacy of intervention therapy for precision medicine in type 1 diabetes
por: Roep, Bart O.
Publicado: (2023)

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
por: Insel, Richard A., et al.
Publicado: (2015)

Early prediction of autoimmune (type 1) diabetes
por: Regnell, Simon E., et al.
Publicado: (2017)

GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells
por: Arif, Sefina, et al.
Publicado: (2020)

Inmunología básica y clínica
por: Peakman, Mark
Publicado: (2011)

Can we vaccinate against Type 1 diabetes?
por: Peakman, Mark
Publicado: (2012)

From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes
por: den Hollander, Nicoline H. M., et al.
Publicado: (2022)

Understanding .NET: a tutorial and analysis
por: Chappell, David
Publicado: (2002)

Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients
por: Coppieters, Ken T., et al.
Publicado: (2012)

Understanding the Unique Microenvironment in the Aging Liver
por: Zhao, Yalei, et al.
Publicado: (2022)

Understanding the Uniqueness of 2p Elements in Periodic Tables
por: Wang, Zhen‐Ling, et al.
Publicado: (2020)

Regulatory Multitasking of Tolerogenic Dendritic Cells – Lessons Taken from Vitamin D3-Treated Tolerogenic Dendritic Cells
por: Nikolic, Tatjana, et al.
Publicado: (2013)

Islet-Resident Dendritic Cells and Macrophages in Type 1 Diabetes: In Search of Bigfoot’s Print
por: Zirpel, Henner, et al.
Publicado: (2021)

Detection and classification of neurons and glial cells in the MADM mouse brain using RetinaNet
por: Cai, Yuheng, et al.
Publicado: (2021)

Persistence is the Twin Sister of Excellence: An Important Lesson for Attempts to Prevent and Reverse Type 1 Diabetes
por: Greenbaum, Carla, et al.
Publicado: (2011)

Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes
por: Lachin, John M., et al.
Publicado: (2011)

Anti–PD-1 Therapy–Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma
por: Samoa, Raynald A., et al.
Publicado: (2020)

Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials
por: Suwandi, Jessica S., et al.
Publicado: (2017)

Islet stress, degradation and autoimmunity
por: Thomaidou, Sofia, et al.
Publicado: (2018)

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential
por: Peakman, Mark, et al.
Publicado: (2010)

Peptide Immunotherapy for Type 1 Diabetes—Clinical Advances
por: Smith, Emma L., et al.
Publicado: (2018)

Think Microsoft .NET
por: DePetrillo, Bart A
Publicado: (2002)

Understanding the impact of pre-analytic variation in haematological and clinical chemistry analytes on the power of association studies
por: Gaye, Amadou, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o2hv47n8hh7bm9uurav12fpthd